Tolrestat in the primary prevention of diabetic neuropathy

Dario Giugliano, Rita Acampora, Raffaele Marfella, Giosué Di Maro, Nicoletta De Rosa, Lucio Misso, Antonio Ceriello, Antonio Quatraro, Felice D'Onofrio

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - To compare the effects of tolrestat and placebo in patients with subclinical diabetic neuropathy. RESEARCH DESIGN AND METHODS - Non- insulin dependent diabetes mellitus (NIDDM) patients with early involvement of the autonomic nervous system were identified by only one pathological (outside the 99% confidence interval of the normal population) squatting test (vagal or sympathetic). Fifty-seven patients entered a randomized, placebo- controlled, double-blind, parallel 52-week study of tolrestat at a dose of 200 mg/day. Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength were assessed throughout the study. RESULTS - At 12 months, nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. At baseline, the squatting vagal test was normal in 16 patients in the tolrestat group and in 15 patients in the placebo group. At 12 months, 25 patients taking tolrestat had a normalized squatting test, but only 6 patients taking placebo did (P = 0.02). Vibration perception threshold improved by a value of 6 ± 3 V in the tolrestat group (P <0.001) and deteriorated by a value of 3 ± 18 V (P <0.001) in the placebo group. CONCLUSIONS - Tolrestat may be useful in the primary prevention of diabetic neuropathy.

Original languageEnglish
Pages (from-to)536-541
Number of pages6
JournalDiabetes Care
Volume18
Issue number4
Publication statusPublished - Apr 1995

Fingerprint

Diabetic Neuropathies
Primary Prevention
Placebos
Vibration
tolrestat
Valsalva Maneuver
Stretch Reflex
Placebo Effect
Autonomic Nervous System
Muscle Strength
Type 2 Diabetes Mellitus
Reflex
Respiration
Research Design
Confidence Intervals
Hypertension
Pressure

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Giugliano, D., Acampora, R., Marfella, R., Di Maro, G., De Rosa, N., Misso, L., ... D'Onofrio, F. (1995). Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care, 18(4), 536-541.

Tolrestat in the primary prevention of diabetic neuropathy. / Giugliano, Dario; Acampora, Rita; Marfella, Raffaele; Di Maro, Giosué; De Rosa, Nicoletta; Misso, Lucio; Ceriello, Antonio; Quatraro, Antonio; D'Onofrio, Felice.

In: Diabetes Care, Vol. 18, No. 4, 04.1995, p. 536-541.

Research output: Contribution to journalArticle

Giugliano, D, Acampora, R, Marfella, R, Di Maro, G, De Rosa, N, Misso, L, Ceriello, A, Quatraro, A & D'Onofrio, F 1995, 'Tolrestat in the primary prevention of diabetic neuropathy', Diabetes Care, vol. 18, no. 4, pp. 536-541.
Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, Misso L et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care. 1995 Apr;18(4):536-541.
Giugliano, Dario ; Acampora, Rita ; Marfella, Raffaele ; Di Maro, Giosué ; De Rosa, Nicoletta ; Misso, Lucio ; Ceriello, Antonio ; Quatraro, Antonio ; D'Onofrio, Felice. / Tolrestat in the primary prevention of diabetic neuropathy. In: Diabetes Care. 1995 ; Vol. 18, No. 4. pp. 536-541.
@article{c26265136f184b26a3268ac4c3ba8471,
title = "Tolrestat in the primary prevention of diabetic neuropathy",
abstract = "OBJECTIVE - To compare the effects of tolrestat and placebo in patients with subclinical diabetic neuropathy. RESEARCH DESIGN AND METHODS - Non- insulin dependent diabetes mellitus (NIDDM) patients with early involvement of the autonomic nervous system were identified by only one pathological (outside the 99{\%} confidence interval of the normal population) squatting test (vagal or sympathetic). Fifty-seven patients entered a randomized, placebo- controlled, double-blind, parallel 52-week study of tolrestat at a dose of 200 mg/day. Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength were assessed throughout the study. RESULTS - At 12 months, nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. At baseline, the squatting vagal test was normal in 16 patients in the tolrestat group and in 15 patients in the placebo group. At 12 months, 25 patients taking tolrestat had a normalized squatting test, but only 6 patients taking placebo did (P = 0.02). Vibration perception threshold improved by a value of 6 ± 3 V in the tolrestat group (P <0.001) and deteriorated by a value of 3 ± 18 V (P <0.001) in the placebo group. CONCLUSIONS - Tolrestat may be useful in the primary prevention of diabetic neuropathy.",
author = "Dario Giugliano and Rita Acampora and Raffaele Marfella and {Di Maro}, Giosu{\'e} and {De Rosa}, Nicoletta and Lucio Misso and Antonio Ceriello and Antonio Quatraro and Felice D'Onofrio",
year = "1995",
month = "4",
language = "English",
volume = "18",
pages = "536--541",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Tolrestat in the primary prevention of diabetic neuropathy

AU - Giugliano, Dario

AU - Acampora, Rita

AU - Marfella, Raffaele

AU - Di Maro, Giosué

AU - De Rosa, Nicoletta

AU - Misso, Lucio

AU - Ceriello, Antonio

AU - Quatraro, Antonio

AU - D'Onofrio, Felice

PY - 1995/4

Y1 - 1995/4

N2 - OBJECTIVE - To compare the effects of tolrestat and placebo in patients with subclinical diabetic neuropathy. RESEARCH DESIGN AND METHODS - Non- insulin dependent diabetes mellitus (NIDDM) patients with early involvement of the autonomic nervous system were identified by only one pathological (outside the 99% confidence interval of the normal population) squatting test (vagal or sympathetic). Fifty-seven patients entered a randomized, placebo- controlled, double-blind, parallel 52-week study of tolrestat at a dose of 200 mg/day. Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength were assessed throughout the study. RESULTS - At 12 months, nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. At baseline, the squatting vagal test was normal in 16 patients in the tolrestat group and in 15 patients in the placebo group. At 12 months, 25 patients taking tolrestat had a normalized squatting test, but only 6 patients taking placebo did (P = 0.02). Vibration perception threshold improved by a value of 6 ± 3 V in the tolrestat group (P <0.001) and deteriorated by a value of 3 ± 18 V (P <0.001) in the placebo group. CONCLUSIONS - Tolrestat may be useful in the primary prevention of diabetic neuropathy.

AB - OBJECTIVE - To compare the effects of tolrestat and placebo in patients with subclinical diabetic neuropathy. RESEARCH DESIGN AND METHODS - Non- insulin dependent diabetes mellitus (NIDDM) patients with early involvement of the autonomic nervous system were identified by only one pathological (outside the 99% confidence interval of the normal population) squatting test (vagal or sympathetic). Fifty-seven patients entered a randomized, placebo- controlled, double-blind, parallel 52-week study of tolrestat at a dose of 200 mg/day. Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength were assessed throughout the study. RESULTS - At 12 months, nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. At baseline, the squatting vagal test was normal in 16 patients in the tolrestat group and in 15 patients in the placebo group. At 12 months, 25 patients taking tolrestat had a normalized squatting test, but only 6 patients taking placebo did (P = 0.02). Vibration perception threshold improved by a value of 6 ± 3 V in the tolrestat group (P <0.001) and deteriorated by a value of 3 ± 18 V (P <0.001) in the placebo group. CONCLUSIONS - Tolrestat may be useful in the primary prevention of diabetic neuropathy.

UR - http://www.scopus.com/inward/record.url?scp=0028943426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028943426&partnerID=8YFLogxK

M3 - Article

C2 - 7497865

AN - SCOPUS:0028943426

VL - 18

SP - 536

EP - 541

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -